- Home
- SMWB vs ARVN Comparison
SMWB vs ARVN Comparison
Compare SMWB & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMWB
- ARVN
- Stock Information
- Founded
- SMWB 2007
- ARVN 2015
- Country
- SMWB Israel
- ARVN United States
- Employees
- SMWB N/A
- ARVN N/A
- Industry
- SMWB Computer Software: Programming Data Processing
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- SMWB Technology
- ARVN Health Care
- Exchange
- SMWB Nasdaq
- ARVN Nasdaq
- Market Cap
- SMWB 747.7M
- ARVN 676.2M
- IPO Year
- SMWB 2021
- ARVN 2018
- Fundamental
- Price
- SMWB $8.40
- ARVN $10.00
- Analyst Decision
- SMWB Strong Buy
- ARVN Buy
- Analyst Count
- SMWB 9
- ARVN 23
- Target Price
- SMWB $14.89
- ARVN $17.75
- AVG Volume (30 Days)
- SMWB 211.8K
- ARVN 2.5M
- Earning Date
- SMWB 11-11-2025
- ARVN 11-05-2025
- Dividend Yield
- SMWB N/A
- ARVN N/A
- EPS Growth
- SMWB N/A
- ARVN N/A
- EPS
- SMWB N/A
- ARVN N/A
- Revenue
- SMWB $268,346,999.00
- ARVN $312,300,000.00
- Revenue This Year
- SMWB $16.98
- ARVN N/A
- Revenue Next Year
- SMWB $14.91
- ARVN N/A
- P/E Ratio
- SMWB N/A
- ARVN N/A
- Revenue Growth
- SMWB 16.06
- ARVN 93.86
- 52 Week Low
- SMWB $6.36
- ARVN $5.90
- 52 Week High
- SMWB $17.64
- ARVN $28.83
- Technical
- Relative Strength Index (RSI)
- SMWB 42.91
- ARVN 58.39
- Support Level
- SMWB $8.24
- ARVN $9.27
- Resistance Level
- SMWB $9.00
- ARVN $10.18
- Average True Range (ATR)
- SMWB 0.44
- ARVN 0.40
- MACD
- SMWB -0.01
- ARVN -0.05
- Stochastic Oscillator
- SMWB 17.73
- ARVN 70.31
About SMWB Similarweb Ltd.
Similarweb Ltd provides digital data and analytics that power critical business decisions. The group recognizes revenue from subscriptions to the platform and other subscription products on a straight-line basis over the term of the contract subscription period beginning on the date access to the platform is granted, provided all other revenue recognition criteria have been met. It has geographic presence in Israel, the United States, the United Kingdom, Asia Pacific, Europe, and Other. The group generates the majority of its revenue from the United States.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.